What We're Reading: Page 417

Industry reads hand-picked by our editors

Jul 09, 2014

The New York Times
Hedge fund nominates Allergan slate as takeover fight escalates

Jul 08, 2014

WSJ
Valeant may have antidote for Allergan's 'poison pill'
biospace.com
FDA puts government-funded ebola study on clinical hold
WSJ
J&J's DePuy Synthes cuts 400 existing jobs, creates 80 new jobs
pharmafile.com
Spectrum does it again, gains approval for another lymphoma drug

Jul 07, 2014

To find more content, use the "Topics" in the menu above.

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Thanks for signing up! Please keep an eye out for a confirmation email from [email protected] To ensure we make it into your inbox regularly, add us to your allow list, mark us as a safe sender, or add us to your address book. Check out more from

Industry Report
Biopharma Firms: Overcome Roadblocks to European Expansion Custom content for Cencora
Podcast
Community Oncology, a Local Lifeline Custom content for McKesson
Survey Report
The State of Process Intensification Custom content for Thermo Fisher Scientific

This website is owned and operated by Informa TechTarget, a global network that informs, influences and connects the world's technology buyers and sellers.

Hedge fund nominates Allergan slate as takeover fight escalates

Valeant may have antidote for Allergan's 'poison pill'

FDA puts government-funded ebola study on clinical hold

J&J's DePuy Synthes cuts 400 existing jobs, creates 80 new jobs

Spectrum does it again, gains approval for another lymphoma drug

Reach our audience

Related Publications

Don't miss tomorrow's biopharma industry news